Stock Traders Purchase High Volume of Put Options on Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) saw some unusual options trading on Tuesday. Stock investors acquired 389 put options on the company. This represents an increase of approximately 232% compared to the typical volume of 117 put options.
A number of brokerages have weighed in on REGN. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective for the company. in a research note on Monday, May 15th. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a report on Monday, May 15th. Cowen and Company reissued a “hold” rating and issued a $380.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Credit Suisse Group AG reissued a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Finally, Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $432.21.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.270% during midday trading on Tuesday, reaching $459.745. 316,944 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $464.40. The stock has a market cap of $48.54 billion, a P/E ratio of 55.652 and a beta of 1.44. The company’s 50-day moving average price is $401.76 and its 200-day moving average price is $383.10.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same period last year, the company posted $2.57 EPS. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post $12.67 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the sale, the director now owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $400,000. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of REGN. Korea Investment CORP boosted its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Live Your Vision LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $157,000. Finally, Blenheim Capital Management BV bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $160,000. 68.83% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.